Boehringer teams up with OSE in €1.1 billion cancer drug partnership
pharmafile | April 5, 2018 | News story | Sales and Marketing | Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma
Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to develop the latter’s candidate for the treatment of advanced solid tumours.
As part of the deal, Boehringer will obtain global rights to OSE-172, OSE’s SIRP-alpha antagonist, in exchange for an up-front payment of €15 million, followed by another sum of €15 million after the drug reaches Phase 1 trials. In its entirety, the deal is worth a potential €1.1 billion when development, commercialisation and sales milestones payments are taken into account.
OSE’s candidate is a monoclonal antibody which operates by targeting the SIRP-alpha receptor expressed in myeloid lineage cells, blocking the CD47 ligand from binding to the receptor and triggering its cellular inhibitory effects.
“We are excited to partner with OSE Immunotherapeutics to develop this promising, novel cancer immunotherapy,” commented Dr Jonathon Sedgwick, Global Head of Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “A key area of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example. We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”
OSE CEO Dr Dominique Costantini also added: “This partnership with Boehringer Ingelheim is a real recognition of the value of our innovative approach to treating cancer and will create an exciting new alliance to fuel the Phase 1 development of OSE-172. Boehringer Ingelheim’s expertise and insights will be invaluable as we step up the clinical development and work to commercialise this new treatment paradigm.”
Matt Fellows
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
